Pharma leader calls for ‘dynamic’ EU drug assessment

“The value of the approach has been proven,” claims AbbVie regulatory policy head

The EU should adopt a “dynamic” approach to assessing potential new drugs, a sector leader has suggested.

Under dynamic regulatory assessment, regulators would look at partial data on drug safety and efficacy as the data are generated, rather than waiting for complete data as at present.